GGrantIndex
← Leaderboards

Robert John Wilkinson

University Of Cape Town

$5,301,802
Attributed
$12,041,833
Total exposure
5
Grants
1
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.2M · FY201525
$2.5M$1.9M$1.3M$625K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$12,041,833 · 5

By mechanism

R01$8,772,066 · 2
U01$2,098,576 · 2
UH2$1,171,191 · 1

Most similar at University Of Cape Town

Same institution · by research overlap

Others in their field

Top investigators on “Cells

Research focus

CellsInfectionMycobacterium TuberculosisTuberculosisResponseImmune ResponseTissuesInflammationMouse ModelTuberculosis TreatmentCytokineSiteBiological MarkersPlasmaCollaborationsSafetyBloodPharmacotherapyImmunologicsPhenotypeIn VitroPathogenesisTuberculosis DrugsMacrophage

Grant awards (22)

Influence of high-dose rifampin on Mycobacterial load and inflammatory mediators in pericardial TB patients$199,994
U01 · FY2025 · AI
Harnessing B cells for TB vaccine development to improve therapy of TB and TB-HIV coinfection$1,273,323
R01 · FY2024 · AI
Translational approaches to improve understanding and outcome in Tuberculous meningitis$747,157
R01 · FY2024 · AI
Harnessing B cells for TB vaccine development to improve therapy of TB and TB-HIV coinfection$1,276,503
R01 · FY2023 · AI
Translational approaches to improve understanding and outcome in Tuberculous meningitis$703,053
R01 · FY2023 · AI
Influence of high-dose rifampin on Mycobacterial load and inflammatory mediators in pericardial TB patients$199,994
U01 · FY2023 · AI
Harnessing B cells for TB vaccine development to improve therapy of TB and TB-HIV coinfection$1,294,431
R01 · FY2022 · AI
Translational approaches to improve understanding and outcome in Tuberculous meningitis$693,318
R01 · FY2022 · AI
Influence of high-dose rifampin on Mycobacterial load and inflammatory mediators in pericardial TB patients$199,994
U01 · FY2022 · AI
Harnessing B cells for TB vaccine development to improve therapy of TB and TB-HIV coinfection$1,297,094
R01 · FY2021 · AI
Translational approaches to improve understanding and outcome in Tuberculous meningitis$736,322
R01 · FY2021 · AI
Influence of high-dose rifampin on Mycobacterial load and inflammatory mediators in pericardial TB patients$199,994
U01 · FY2021 · AI
Translational approaches to improve understanding and outcome in Tuberculous meningitis$750,865
R01 · FY2020 · AI
Influence of high-dose rifampin on Mycobacterial load and inflammatory mediators in pericardial TB patients$199,994
U01 · FY2020 · AI
Inflammatory determinants of disease severity and treatment outcome in TB patients$151,636
U01 · FY2019 · AI · contact PI
Inflammatory determinants of disease severity and treatment outcome in TB patients$296,865
U01 · FY2018 · AI · contact PI
Inflammatory determinants of disease severity and treatment outcome in TB patients$162,700
U01 · FY2017 · AI · contact PI
Inflammatory determinants of disease severity and treatment outcome in TB patients$147,254
U01 · FY2017 · AI · contact PI
Rational Design of Combination Regimens Targeting Both Host and Pathogen$571,191
UH2 · FY2016 · AI
Inflammatory determinants of disease severity and treatment outcome in TB patients$165,437
U01 · FY2016 · AI · contact PI
Rational Design of Combination Regimens Targeting Both Host and Pathogen$600,000
UH2 · FY2015 · AI
Inflammatory determinants of disease severity and treatment outcome in TB patients$174,714
U01 · FY2015 · AI · contact PI